Analysis of genomic abnormalities in CLL, DLBCL-RS, and de novo DLBCL demonstrated that cell cycle deregulation via inactivation of TP53 and CDKN2A is a main driver of the transformation from CLL to aggressive lymphoma [30]. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.